Item 8.01. Other Events.
On August 15, 2022, Halozyme Therapeutics, Inc. (the "Company") issued a press
release announcing that it proposes to offer, subject to market conditions and
other factors, $500.0 million aggregate principal amount of convertible senior
notes due 2028 (the "Convertible Notes"). The Company expects to grant to the
initial purchasers an option to purchase up to an additional $75.0 million
aggregate principal amount of Convertible Notes. A copy of the press release is
attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release dated August 15, 2022
104 Inline XBRL for the cover page of this Current Report on Form 8-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses